BioLineRx (BLRX) Closes BL-8040 In-License Agreement

On September 4, 2012, BioLineRx Ltd. (Nasdaq: BLRX) entered into an agreement (the “Agreement”) with Biokine Therapeutics Ltd. to in-license the rights to BL-8040 for the treatment of acute myeloid leukemia, as well as other types of hematological cancer. The closing of the transaction was subject to formal approval of the Office of the Chief Scientist of Israel’s Ministry of Industry, Trade and Labor (the “OCS”). The approval of the OCS was obtained on January 14, 2013, and therefore the transaction has now closed and the Agreement has become effective according to its terms.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA Committee Recommends To Widen Access To Bpc-157 Peptide
• BioLineRx and Hemispherian to present GLIX1 ovarian cancer data at ESMO
• Brown-Forman declares quarterly dividend, elects directors at annual meeting